65% of nosocomial bacterial infections are currently caused by six pathogenic species classified under the acronym ‘ESKAPE’, as they elude the action of most classes of available antibiotics by developing multidrug resistance mechanisms.
ACT ON BACT is putting forward two classes of synthetic compounds with new structures characterised by original action mechanisms limiting the rapid acquisition of resistance by the bacteria.
– Strong activity regarding the multidrug-resistant Staphylococcus and Enterococcus species
– Original action mechanisms
– Efficient and rapid syntheses
– Low cost
Antibacterial activity of the two families was evaluated in vitro.
Improved solubility to reduce the plasma protein binding
Identification of action mechanisms
Low spontaneous mutation rates: 10-7 to 10-9 In vivo Studies planned with animal models.
– Pharmaceutical application: applications in systemic treatment (original structures and modes of action)